Profil
Dr. Stephan Rapp joined SHS in 2008 as investment manager.
Before joining SHS, Dr. Rapp was director of the Blood Donor Center of BRK and 'Manager Clinical Operations EU' with Genetics Institute/Wyeth.
He studied biology at and received a PhD in biochemistry from the University of Heidelberg.
Dr. Rapp earned a degree in financial analysis and in asset management (CEFA, CIIA) at DVFA.
Ehemalige bekannte Positionen von Stephan Rapp
| Unternehmen | Position | Ende |
|---|---|---|
SHS Gesellschaft für Beteiligungsmanagement mbH
 SHS Gesellschaft für Beteiligungsmanagement mbH Investment ManagersFinance SHS Gesellschaft für Beteiligungsmanagement mbH (SHS) is an independent private equity and venture capital firm founded by Bernhard Schirmers and Reinhilde Spatscheck in 1993, and was headquartered in Tübingen, Baden-Württemberg in the southwest of Germany. | Private Equity Investor | 01.01.2010 |
NEUWAY Pharma GmbH
 NEUWAY Pharma GmbH Pharmaceuticals: MajorHealth Technology NEUWAY Pharma GmbH develops treatments for central nervous system diseases. The firm offers preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases. The company was founded in April 2014 and is headquartered in Bonn, Germany. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
SHS Gesellschaft für Beteiligungsmanagement mbH
SHS Gesellschaft für Beteiligungsmanagement mbH Investment ManagersFinance SHS Gesellschaft für Beteiligungsmanagement mbH (SHS) is an independent private equity and venture capital firm founded by Bernhard Schirmers and Reinhilde Spatscheck in 1993, and was headquartered in Tübingen, Baden-Württemberg in the southwest of Germany. | Finance |
NEUWAY Pharma GmbH
NEUWAY Pharma GmbH Pharmaceuticals: MajorHealth Technology NEUWAY Pharma GmbH develops treatments for central nervous system diseases. The firm offers preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases. The company was founded in April 2014 and is headquartered in Bonn, Germany. | Health Technology |
